A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

What’s the reason for this? Your nasal cavity contains many blood vessels, which provide a more direct route for the drug into your bloodstream. When a drug is directly absorbed into your ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...